Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;192(2):569-574.
doi: 10.1007/s11845-022-03023-9. Epub 2022 May 10.

Strontium-89 chloride delivery for painful bone metastases in patients with a history of prior irradiation

Anneyuko I Saito  1 , Tatsuya Inoue  2 , Makiko Kinoshita  3 , Takahiro Kosaka  3 , Taira Mitsuhashi  3
Affiliations

Strontium-89 chloride delivery for painful bone metastases in patients with a history of prior irradiation

Anneyuko I Saito et al. Ir J Med Sci. 2023 Apr.

Abstract

Background: Re-irradiation of a previously irradiated site must be done with careful consideration to minimize dose to organs at risk.

Aims: To evaluate pain response and safety of Sr-89 administration for painful bone metastases after prior irradiation.

Methods: We retrospectively reviewed patients with Sr-89 injection for painful bone metastasis in a previously irradiated site. All patients were seen in follow-up at 1, 2, 3, and 4 months after injection and every 6 months thereafter. Pain control, toxicity, and pain progression-free survival were analyzed. Correlation of pain relapse with the following characteristics was analyzed: gender, age, primary tumor, tumor pathology, baseline performance status, and baseline verbal rating scale.

Results: Among 25 patients analyzed (10 male, 15 female), median age was 68 (range, 50-81) years. Primary tumor sites included lung (n = 11), breast (n = 3), uterine cervix (n = 3), prostate (n = 3), and others (n = 5). Median follow-up was 25 (range, 1-76) months. Pain relief was observed in 24 patients (96.0%). One- and 2-year pain progression-free survival rates in these patients were 54.5% and 48.4%, respectively. Median time to pain progression was 5 (range, 2-16) months. Statistically significantly lower pain progression-free survival was observed in patients with osteolytic bone metastases (p < 0.01). No grade 3 or worse adverse events were observed.

Conclusion: Sr-89 injection showed pain relief in most of our patients with painful bone metastases in a previously irradiated site and caused no grade 3 or worse adverse events. Sr-89 is an option for patients with a painful bone metastasis in a previously irradiated site.

Keywords: Bone metastasis; Re-irradiation; Strontium-89 chloride.

PubMed Disclaimer

References

    1. Taylor AJ Jr (1994) Strontium-89 for the palliation of bone pain due to metastatic disease. J Nucl Med 35:2054 - PubMed
    1. Annex 1: Evaluation of pain WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. World Health Organization https://apps.who.int › handle › 9789241550390-eng Accessed Nov 13th 2021
    1. Common Terminology Criteria for Adverse Events (CTCAE) v5. National cancer institute https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm Accessed Nov 13th 2021
    1. Chow E, Hoskin P, Mitera G et al (2012) Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Int J Radiat Oncol Biol Phys 82:1730–1737. https://doi.org/10.1016/j.ijrobp.2011.02.008 - DOI - PubMed
    1. Furubayashi N, Negishi T, Ura S et al (2015) Palliative effects and adverse events of strontium-89 for prostate cancer patients with bone metastasis. Mol Clin Oncol 3:257–263. https://doi.org/10.3892/mco.2014.449 - DOI - PubMed

LinkOut - more resources